About us
Luminesce Alliance is a not-for-profit cooperative joint venture established with the support of the NSW Government to coordinate and integrate precision medicine research for children with cancer, rare diseases and neurodevelopmental disorders.
Our partners
Our Vision, Mission and Purpose
Our Principles
Our History
Paediatrio established
Luminesce Alliance was originally established in March 2015 as Peadiatrio, an independent organisation founded by the Sydney Children’s Hospitals Network (SCHN), Children’s Cancer Institute, and Children’s Medical Research Institute (CMRI) to coordinate and integrate paediatric research in NSW.
Paediatrio was formally launched at Parliament House in December 2016. Download invitation
- June 2018 – Paediatrio secures $2 million of NSW Government funding to support more than 200,000 babies in a two-year pilot for Spinal Muscular Atrophy (SMA) screening; and $1 million of NSW Government funding for the INFORM2 Trial
- September 2018 – Paediatrio secures $2 million of NSW Government funding to establish cGMP-grade viral vector manufacturing in New South Wales for quick deployment in paediatric gene therapy trials, targeting cancer and rare genetic diseases
$24m funding for Paediatric Precision Medicine Program 2019-2023
- February 2019 – Paediatrio is awarded $24m funding by the NSW Government for the (Luminesce Alliance) Centre for Paediatric Medicine: Paediatric Precision Medicine Program
- February 2019 – the UNSW Sydney and Sydney University become affiliated partners
- September 2019 – Paediatrio establish Australia’s first stem cell and organoid facility
- September 2019 – Paediatrio rebrands to become Luminesce Alliance
- World first study on supporting doctors treating paediatric cancer patients: The hopes and challenges of precision medicine for children with cancer
- Luminesce Alliance seed funding outcomes: Fifty-nine applications were received with a total funding request of just under $11 million
- INFORM2 Trial opens in Australia
- Parlimaentary Response – Approval processes for new drugs and novel medical technologies for rare diseases
- Partnering with the NSW Department of Education to promote the STEM workforce
- Luminesce Alliance funded Spinal Muscular Atrophy (SMA) gene therapy project ranked top idea by NHMRC Ideas Grant for 2020
- Luminesce Alliance initial funding to establish the CMRI Stem Cell and Organoid Facility has attracted further funding for inherited retinal conditions
- Human mini-hearts developed to study diseases and potential treatments
- Novel RNA diagnostic testing for rare genetic diseases gains global attention as GIM’s Most Read 2022 Paper on RNA Diagnostics
- Gene therapy and diagnosis break-through for retinal genetic eye diseases
- Lab-grown mini organs advance eye and brain disease research
- LA takes a lead on Rett Syndrome – fishing for biomarkers
- A success story of translation: screening babies nationally for spinal muscular atrophy
$20m funding for Enabling Platforms Program 2023-2027
- Successful completion of the four-year Paediatric Precision Medicine Program 2019-2023
- NSW Health allocates $20M in funding for Luminesce Alliance Enabling Platforms Program 2023 – 2027
- Predict cancer predisposition trial publishes first protocol paper
- Luminesce Alliance and Child UnLimited form partnership
- Expressions of Interest invited to use the services of Luminesce Alliance Enabling Platforms:
- Luminesce Alliance Conference 2024: Paediatric Precision Medicine: Advancing research and patient care on 7-8 November 2024 at the UNSW Sydney, Australia